Literature DB >> 8725004

Ibogaine-like effects of noribogaine in rats.

S D Glick1, S M Pearl, J Cai, I M Maisonneuve.   

Abstract

Ibogaine is a naturally occurring alkaloid that has been claimed to be effective in treating addiction to opioids and stimulants; a single dose is claimed to be effective for 6 months. Analogously, studies in rats have demonstrated prolonged (one or more days) effects of ibogaine on morphine and cocaine self-administration even though ibogaine is mostly eliminated from the body in several hours. These observations have suggested that a metabolite may mediate some of the effects of ibogaine. Recently, noribogaine was identified as a metabolite of ibogaine. Accordingly, the present study sought to determine, in rats, whether noribogaine had pharmacological effects mimicking those of ibogaine. Noribogaine (40 mg/kg) was found to decrease morphine and cocaine self-administration, reduce the locomotor stimulant effect of morphine, and decrease extracellular levels of dopamine in the nucleus accumbens and striatum. All of these effects were similar to effects previously observed with ibogaine (40 mg/kg); however, noribogaine did not induce any ibogaine-like tremors. The results suggest that noribogaine may be a mediator of ibogaine's putative anti-addictive effects.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8725004     DOI: 10.1016/0006-8993(95)01563-9

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  9 in total

1.  In vitro activities of iboga alkaloid congeners coronaridine and 18-methoxycoronaridine against Leishmania amazonensis.

Authors:  Jan Carlo Delorenzi; Leonardo Freire-de-Lima; Cerli R Gattass; Deise de Andrade Costa; Liwen He; Martin E Kuehne; Elvira M B Saraiva
Journal:  Antimicrob Agents Chemother       Date:  2002-07       Impact factor: 5.191

Review 2.  Novel pharmacotherapeutic treatments for cocaine addiction.

Authors:  Daryl Shorter; Thomas R Kosten
Journal:  BMC Med       Date:  2011-11-03       Impact factor: 8.775

3.  Noribogaine, but not 18-MC, exhibits similar actions as ibogaine on GDNF expression and ethanol self-administration.

Authors:  Sebastien Carnicella; Dao-Yao He; Quinn V Yowell; Stanley D Glick; Dorit Ron
Journal:  Addict Biol       Date:  2010-10       Impact factor: 4.280

4.  Glial cell line-derived neurotrophic factor mediates the desirable actions of the anti-addiction drug ibogaine against alcohol consumption.

Authors:  Dao-Yao He; Nancy N H McGough; Ajay Ravindranathan; Jerome Jeanblanc; Marian L Logrip; Khanhky Phamluong; Patricia H Janak; Dorit Ron
Journal:  J Neurosci       Date:  2005-01-19       Impact factor: 6.167

5.  Pharmacological comparison of the effect of ibogaine and 18-methoxycoronaridine on isolated smooth muscle from the rat and guinea-pig.

Authors:  M K Mundey; N A Blaylock; R Mason; S D Glick; I M Maisonneuve; V G Wilson
Journal:  Br J Pharmacol       Date:  2000-04       Impact factor: 8.739

Review 6.  GDNF--a potential target to treat addiction.

Authors:  Sebastien Carnicella; Dorit Ron
Journal:  Pharmacol Ther       Date:  2008-12-24       Impact factor: 12.310

7.  Effect of Iboga alkaloids on µ-opioid receptor-coupled G protein activation.

Authors:  Tamara Antonio; Steven R Childers; Richard B Rothman; Christina M Dersch; Christine King; Martin Kuehne; William G Bornmann; Amy J Eshleman; Aaron Janowsky; Eric R Simon; Maarten E A Reith; Kenneth Alper
Journal:  PLoS One       Date:  2013-10-16       Impact factor: 3.240

Review 8.  Ibogaine and addiction in the animal model, a systematic review and meta-analysis.

Authors:  M Belgers; M Leenaars; J R Homberg; M Ritskes-Hoitinga; A F A Schellekens; C R Hooijmans
Journal:  Transl Psychiatry       Date:  2016-05-31       Impact factor: 6.222

Review 9.  The iboga enigma: the chemistry and neuropharmacology of iboga alkaloids and related analogs.

Authors:  Rishab N Iyer; David Favela; Guoliang Zhang; David E Olson
Journal:  Nat Prod Rep       Date:  2021-03-04       Impact factor: 13.423

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.